Researchers and patient advocates from the Monell Chemical Senses Center, Smell and Taste Association of North America (STANA), and Thomas Jefferson University came together during the COVID-19 pandemic to incorporate patient voices in efforts to prioritize research areas focused on improving care for people with smell and taste disorders.
To this end, in 2022 these collaborators conducted a survey and listening sessions with patients, caregivers, and family members affected by impaired smell or taste. They asked about their individual perceptions of the effectiveness of treatments, among other topics. Using an online questionnaire, over 5,800 people in the U.S. – from all 50 states and the District of Columbia – answered the team’s call to action. The survey results and critical areas for related research are published in Chemical Senses.
Overall their findings underscore the importance of conducting more large-scale, randomized clinical trials that include older participants. They also identified a need to parse results among anosmia, hyposmia, and parosmia to better understand the mechanisms underlying each diagnosis.
Patient voices sound the urgency for fundamental research on what underlies sensory disorders and how that can be translated into new and better treatments.
Senior author Nancy E. Rawson, PhD, Monell Executive Vice President & Chief Impact Officer
The team, which also includes researchers from San Diego State University, analyzed the characteristics that predicted whether treatment for smell or taste disorders was reported as effective (or not) for patients aged 18-24, 25-39, 40-60 and 60+ years. No treatments were highly effective. Collectively, the survey participants reported being treated with nasal steroids, oral steroids, zinc, nasal rinse, smell training, theophylline, platelet rich plasma, and Omega 3. The most consistent predictor of low effectiveness was age. The majority of those 40-60 and 60+ years old reported that nasal steroids, oral steroids, zinc, nasal rinse, and smell training were only slightly effective or not effective at all. However, many of these treatment strategies target cell regeneration and immune response, functions that can diminish with age. Only those under the age of 40 reported more-than-slight efficacy of steroids or smell training.
“The overwhelming response of nearly 6,000 people with smell loss and their family members is indicative of how many people are craving for more information and to be heard.”
The survey’s age-related data has important implications for clinical trials that measure treatment effectiveness, emphasizing the need to include patients of all ages. In addition, other studies have shown that older adults with olfactory impairment have an increased risk for Alzheimer’s disease (AD) and other neurodegenerative disorders. The authors of this Chemical Senses article surmise that olfactory impairment associated with long COVID could lead to a significant rise in AD incidence, making clinical research on new treatments for smell loss a key priority.
The efficacy of nasal steroids and smell training was also influenced by the type of diagnosis patients received: People with complete loss of smell (anosmia) rated the training less effective than those with a partial loss (hyposmia), and those with a distorted sense of smell (parosmia) rated nasal steroids less effective than those with hyposmia. Interestingly, people who were unsure of their diagnosis rated smell training as being less effective than those who were diagnosed with a partial loss of smell.
The authors report that in small-group listening sessions, patients from different survey sub-groups, such as those with complete or partial smell loss, shared individual stories on topics that impacted their day-to-day lives. They expressed:
A need to know the cause of their disorders and evidence that a particular treatment is effective.
An interest in smell testing with their primary care physician.
An enthusiasm for participating in clinical trials.
Frustration with treatment strategies that produce little if any benefit and suggesting that new treatments should be tried.
“From the patient survey and listening sessions, we learned that patients have an important and unique perspective based on their own lived experiences that researchers and clinicians should consider,” said co-author Katie Boateng, STANA President. “In particular, patients want to be involved in identifying treatments that directly address impacts on their quality of life.”
This concerted study of patient-centered approaches to combat smell and taste disorders started with a 2020 white paper that summarized research needs for chemosensory disorders. These details were identified at a 2018 meeting held at the Monell Center with clinicians, researchers, and patients. Fast forward two years: COVID dramatically changed the awareness of the loss of smell and taste, a principal, early symptom of infection.
Looking forward, the team suggests a number of priorities for future research:
Developing partnerships among patients, clinicians, and basic scientists to align priorities for research, education, and health care standards.
Increasing accessibility and use of standardized testing methods for diagnosing smell and taste disorders.
Clinical studies of emerging therapeutics need to consider a wide range of ages to address changing capacity for regeneration.
Health care professionals in a wide range of disciplines – from dentistry to nutrition to otolaryngology – need to be provided with training in management of patients with taste and smell disorders.
These patient voices contributed much to our understanding of olfactory disorders – and their symptoms, diagnoses, treatments, and quality-of-life issues.
Gurston G. Nyquist, MD, Professor of Otolaryngology and Neurological Surgery at Jefferson
“We need to find ways to partner with patients as we plan future research.” Gurston G. Nyquist added.
Along with Rawson, Boateng, Nyquist, and Murphy, co-authors are Conner Frank and Abigail Albertazzi, San Diego State University; Paule V. Joseph, National Institute of Alcohol Abuse and Alcoholism and National Institute of Nursing; Bita Naimi and Emily Garvey, Thomas Jefferson University; Suz Schrandt, ExPPect, LLC, Arlington, VA; Pamela Silberman, the Smell and Taste Association of North America; and Pamela Dalton, Stephanie Hunter, and Jenifer Trachtman, Monell Center.
This work was supported by the PCORI Engagement Contract (EASC #00261) and the National Institute on Aging (R01AG062006-05). PCORI is an independent, nonprofit organization authorized by Congress to fund research that will provide patients, their caregivers, and clinicians with the evidence-based information needed to make better-informed healthcare decisions.
Other funds provided by the Division of Intramural Research, the National Institute on Alcohol Abuse and Alcoholism (Z01AA000135), the National Institute of Nursing Research and the Office of Workforce Diversity, the National Institutes of Health Distinguished Scholar award, and a Rockefeller University Heilbrunn Nurse Scholar Award.
In the summer of 2023, the Monell Chemical Senses Center, Smell and Taste Association of North America, and Thomas Jefferson University finalized an agreement to collaborate in order to improve the lives of people with smell and taste loss and distortion. This agreement formally connects the three partners with a shared vision that can be used as a template by others to facilitate patient-centered outcomes research across the U.S. The 2022 patient engagement survey and the 2024 Chemical Senses article are products of the PCORI Engagement Contract.
(Newswise/TAB)
